Expedition Therapeutics

Expedition Therapeutics

HealthSan Francisco, United States

Expedition Therapeutics is a biotechnology company focused on developing innovative therapies for chronic obstructive pulmonary disease (COPD). The company is notable for its lead therapy, EXPD-101, which targets inflammation in the lungs, aiming to intervene earlier in the disease process rather than just alleviating symptoms. The recent $115 million Series B financing will support the launch of a global Phase 2 clinical trial for this treatment.

$115M · Series BVisit website ↗

🏆 Featured in Datapile’s Q3 2026 USA Funding Report

Read the Q3 2026 USA report →
Add this badge to your site
<a href="https://datapile.co/reports/q3-2026-usa-startup-funding" target="_blank" rel="noopener" style="display:inline-flex;align-items:center;gap:8px;padding:9px 16px;border-radius:9999px;background:#0B1224;color:#ffffff;font:600 13px/1.2 -apple-system,BlinkMacSystemFont,'Segoe UI',Roboto,Arial,sans-serif;text-decoration:none;border:1px solid #7C5CFF"><span style="display:inline-block;width:11px;height:11px;border-radius:3px;background:#7C5CFF"></span>Featured in Datapile&rsquo;s Q3 2026 USA Funding Report</a>

Funding history

  1. $115MSeries B2026-08-06
    Source: news.google.com

Founder

Yi Larson
Yi Larson
Founder and CEO

Investors in Expedition Therapeutics

Backers from this company's tracked funding rounds.

  • General Atlantic
  • RA Capital
  • Vivo Capital
  • Sofinnova Investments
  • Balyasny Asset Management
  • Logos Capital
  • Sanofi Ventures
  • Novo Holdings

More Health companies

Recently funded startups in the same category.

Related on Datapile